# ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

> **NCT04471974** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Rahul Aggarwal** · enrollment: 61 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Metastatic Prostate Small Cell Carcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** BET Bromodomain Inhibitor ZEN-3694
- **DRUG:** Enzalutamide
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04471974
- **Lead sponsor:** Rahul Aggarwal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-26
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471974, "ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04471974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*